Apr 01, 2019
CLS Therapeutics Announces Presentation on “Frontiers in Cancer Immunotherapy” At The New York Academy Of Sciences

NEW YORK, April 1, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Frontiers in Cancer Immunotherapy” being held on May 14-15, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed) encoding DNase I of the treatment of pancreatic cancer animal model.

Apr 07, 2021

NEW YORK, NY /  April 06, 2021 / CLS Therapeutics,  cancer gene therapy company utilizing a novel therapeutic target, announces presentation at the upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.

Aug 06, 2019

CLS Therapeutics Inc., an oncology focused gene therapy company, today announced that their project was selected as one of the 15 finalists to compete for the Boehringer Ingelheim Innovation Prize during the evening of August 15 at NYU Langone Health.

Mar 28, 2019

NEW YORK, March 28, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Targeting Tumor Heterogeneity” being held on May 8, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed ) encoding DNase I of the treatment of pancreatic cancer animal model.